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Abstract
Background & Aims: Patients with primary sclerosing cholangitis (PSC)
frequently highlight the impact of fatigue on their life quality. The study
aims were to evaluate fatigue and its associations in PSC and investigate
whether overt autonomic dysfunction contributes to the expression of
fatigue. Methods: All PSC patients under active follow-up at a regional liver
centre were sent disease- and symptom-assessment tools. Three control
groups were utilized; unselected community controls, patients with inflam-
matory bowel disease (IBD) without PSC, and cholestatic controls with pri-
mary biliary cirrhosis (PBC). A representative subgroup of PSC patients and
normal controls underwent formal autonomic assessment. Results: Symp-
tom-assessment tools were returned by 40 non-transplanted patients.
PSC patients had significantly worse fatigue than population controls
(P = 0.005). Fatigue was significant compared to population controls
whether or not patients had accompanying IBD, although was more marked
in those with both PSC and IBD. In patients with PSC and IBD, fatigue
severity and autonomic symptoms were significantly increased in those with
prior significant surgical intervention. Clinically significant autonomic dys-
function was seen in 22.5% of PSC patients, and of those, 78% had signifi-
cant fatigue. Neurally mediated hypotension was found in 60% of PSC
patients compared to 8% in the control group. The PSC group had increased
sympathetic activity and reduced parasympathetic activity. Conclusion: Fati-
gue is a significant problem in a minority of PSC patients and appears to be
associated with autonomic dysfunction. Fatigued PSC patients should be
screened for autonomic dysfunction and targeting such dysfunction repre-
sents a potential approach to treatment which warrants further exploration.
See Editorial on Page 1489
Primary sclerosing cholangitis (PSC) is a chronic chole-
static condition predominantly affecting males (1). The
underlying pathological process is inflammation and pro-
gressive fibrosis, with stricturing of both intrahepatic and
extrahepatic bile ducts causing chronic cholestasis, even-
tually resulting in cirrhosis. There are currently no treat-
ments effective in slowing progression of PSC to end-
stage disease, the only treatment for which is transplanta-
tion. Cholangiocarcinoma development is another signif-
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icant complication of PSC, as is the development of colo-
nic carcinoma, often in the context of associated inflam-
matory bowel disease (IBD) (2). The aetiology of PSC is
uncertain, as are the relative contributions of genetic and
environmental factors to pathogenesis (3).
While the principal clinical focus in PSC is, rightly, on
the risks of disease progression and associated cancers,
patients themselves frequently highlight the impact of sys-
temic symptoms such as fatigue on their life quality (4).
Patient reports in PSC mirror, in many regards, those in
primary biliary cirrhosis (PBC), another chronic cholestat-
ic condition in which fatigue is an important and well-
characterised problem (5, 6). The actual impact of fatigue
in population terms in PSC is, however, unclear with only
a limited number of studies undertaken with often con-
trasting findings regarding fatigue severity and accompany-
ing life quality impact (7–10), and the response to specific
therapies (11). Furthermore, it is currently unclear as to
what processes might underlie fatigue in PSC. In the case
of both PBC and other chronic liver diseases these include
sleep disturbance [in particular daytime somnolence (12,
13)] and autonomic nervous system dysfunction, relating
in particular to vasomotor control (14–18). In PSC, there
is also the potential for associated clinical conditions such
as IBD and anaemia, which are themselves associated with
fatigue, to contribute to overall symptom burden.
The aim of this study was to evaluate fatigue and its
associations in a comprehensive cohort of PSC patients.
Furthermore, we investigated autonomic and cardiovas-
cular responses in PSC subjects to explore whether auto-
nomic dysfunction is a feature of PSC and whether this
is associated with fatigue severity as is the case in PBC
and non-alcoholic fatty liver disease (NAFLD) (14).
Patients and methods
Subjects
Patients with PSC currently under active follow-up at a
regional liver centre were identified using a comprehen-
sive case-finding approach. Patients under follow-up
following liver transplantation for PSC were also identi-
fied and are reported separately. All participants pro-
vided written informed consent. This study was
approved by the Newcastle and North Tyneside Local
Research Ethics Committees (approval 05/Q0906/205, 1
June 2006). The diagnosis of PSC was made on the basis
of characteristic ERCP or MRCP findings and compati-
ble liver histology (where available), along with consis-
tent abnormalities in liver function tests (LFTs), with all
patients having an alkaline phosphatase (ALP) of >1.59
ULN at diagnosis. All PSC patients were investigated by
colonoscopy at diagnosis for the presence of inflamma-
tory bowel disease (IBD), with biopsies undertaken as
clinically indicated at the time of the investigation. The
presence of microscopic IBD led to patients being cate-
gorized as having IBD for the purposes this study
groups. In addition, patients with colonic symptoms
developing during follow-up were also investigated with
colonoscopy. Most recent blood biochemistry and hae-
matology were retrieved and reviewed. Three control
groups were utilized. Members of the local population
were invited to participate and recruited via notices in
the press. These were community controls as they were
not screened positively or negatively for intercurrent
diseases and/or relevant therapy. Patients with IBD, all
of whom had extensive colitis (defined for the purposes
of this study as extending beyond proctitis) that was
either quiescent or mildly active (defined histologically),
had had PSC actively excluded and had normal liver
biochemistry and bile duct imaging on MRCP, were
recruited from the specialist clinic of the investigators.
The IBD patients were age- and sex-matched to the PSC
patients with IBD at a group level. The third group was
age- and sex-matched PBC patients from the local PBC
clinic.
Symptom-assessment tools
All symptom-assessment tools have been validated for
self-completion and used previously in patients with
liver disease.
Fatigue Impact Scale
The Fatigue Impact Scale (FIS) is a 40-item generic fati-
gue impact scale that was used to assess fatigue severity
in the PSC and control groups. The FIS has previously
been extensively utilized in both normal controls and
PSC populations (19).
Epworth Sleepiness Scale
Daytime somnolence was assessed using the Epworth
Sleepiness Scale (ESS, possible score range 0–24) (20).
A score of 10 or more in this fully validated scale is
indicative of significant daytime hyper-somnolence. A
score of ≥5 and <10 was regarded as being indicative of
moderate daytime hyper-somnolence.
Key Points
• Patients with primary sclerosing cholangitis (PSC)
have significantly worse fatigue than community con-
trols which impacts on their life quality.
• The level of fatigue experienced correlates directly
with the autonomic dysfunction symptom severity.
• Dynamic autonomic testing suggested a shift in
the balance of autonomic reactivity from parasympa-
thetic (down-regulated) to sympathetic (up-regu-
lated).
• At risk patients can be identified using autonomic
dysfunction screening tools which are very acceptable
to patients and can be used in the ordinary clinic set-
ting. Well-described orthostatic intolerance treatment
paradigms may offer possible approaches to therapy.
Liver International (2015)
© 2014 The Authors. Liver International Published by John Wiley & Sons Ltd1634
PSC fatigue is associated with autonomic dysfunction Dyson et al.
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) is a
14-item measure of current anxiety (HADS-A) and
depression (HADS-D). The HADS was specifically
developed for use in physical illness by excluding items
related to somatic symptoms. In this study, a HADS
score >10 was used for definition of case-ness.
Autonomic Dysfunction Symptoms (COMPASS)
The frequency and severity of symptoms of autonomic
dysfunction were assessed using the Composite Auto-
nomic Symptom Scale (COMPASS) (21). The COM-
PASS consists of 73 questions grouped into domains
relating to individual aspects of the autonomic nervous
system weighted according to clinical relevance (21). In
all domains, higher scores indicate a greater symptom
load. COMPASS has been fully validated against labora-
tory-based haemodynamic autonomic function tests
and has been used to investigate autonomic dysfunction
in a variety of diseases (22).
Objective assessment of autonomic parameters
Ten non-transplanted PSC patients, selected to be repre-
sentative of the PSC population as a whole using a
matrix approach, and age- and sex-matched controls
underwent formal autonomic assessment with investiga-
tion for neurally mediated hypotension using our previ-
ously described protocol (15, 23). All investigations
were performed at the same time of day, and took place
in a warm, quiet room. All cardiovascular assessments
were carried out with continuous heart rate (HR) and
beat-to-beat blood pressure (BP) measurement (Task-
force, CN Systems, AHG Health, Somerset West, South
Africa). Orthostatic hypotension (fall of >20 mmHg
systolic or 10 mmHg diastolic on orthostasis) and vaso-
vagal syncope (loss of consciousness resulting from bra-
dycardia induced during the tilt) were diagnosed using
recognized diagnostic criteria (15, 23).
Data analysis
All data were normally distributed (D’Agostino & Pear-
son) and are presented as mean and standard deviation.
Data were analysed using Graphpad software (Prism,
GraphPad Software Inc., La Jolla, CA, USA). Comparisons
between individual patient groups were by student’s
t-tests, and proportions of groups by chi-squared test. Cor-
relations between variables were by Spearman Rank test. A
statistically significant result was taken when P < 0.05.
Results
All patients with a confirmed diagnosis of PSC and still
under follow-up between 1998 and 2012 were identified
(n = 81). Fully completed symptom-assessment tools
were returned by 51 patients. Eleven of these patients
had undergone liver transplantation and were assessed
separately. Median follow-up was 5.23 years (range 0–
19 years). Table 1 shows the demographic details and
distribution of subtypes of cholangiopathy of the non-
transplanted PSC study group (n = 40).
Symptoms and their associations in PSC
The non-transplanted PSC group had significantly
worse fatigue scores than the community controls
(n = 40; Fig. 1a). Fatigue levels were lower than in age
and sex-matched PBC patients (n = 40), although the
difference was not significant. Using an age- and gen-
der-relevant cut-off for significant fatigue based on the
control population, 35% of the PSC patients were found
to be fatigued (Fig. 1b). The demographic distribution
for fatigued PSC patients mirrored the patient group as
a whole. In PSC patients, unlike PBC controls, daytime
somnolence scores were not significantly elevated
(Fig. 2a). In contrast, significant autonomic dysfunction
symptoms were seen (Fig. 2b), with nine PSC patients
(22.5%) exceeding the previously defined cut-off for
clinically significant autonomic dysfunction in the con-
text of chronic fatigue (24). Moreover, the level of fati-
gue experienced by PSC patients correlated directly with
the autonomic dysfunction symptom severity (Fig. 2c).
Seven of those nine (78%) PSC patients with significant
autonomic dysfunction symptoms had significant fati-
gue, compared with only 7 of 31 (22.5%) of the group
without significant autonomic dysfunction (P < 0.005;
Table 1. Demographic details and distribution of subtypes of chol-
angiopathy in the non-transplanted PSC study group (n = 40). Fig-
ures in brackets for blood parameters refer to the standard
deviation.
Demographic details
Males (%) 31 (78%)
Mean age (SD) years 51 (13)
Concurrent inflammatory bowel disease (IBD) (%) 24 (60%)
Blood parameters
Albumin (g/L) 41 (7)
Alkaline Phosphatase (U/L) 275 (248)
Bilirubin (micromol/L) 31 (53)
Alanine Aminotransferase (U/L) 62 (49)
Random Glucose (mmol/L) 6.1 (2.6)
Platelets (9103/mm3) 242 (138)
Immunoglobulin G (IgG) 15 (4.1)
Follow-up years 5.2 (0–19)
Number of medications 4.5 (3.6)
Distribution of subtypes of cholangiopathy
Small duct PSC 11 (28%)
Large duct PSC
Total 27 (68%)
Extrahepatic disease 1 (3%)
Intrahepatic disease 9 (23%)
Both 17 (43%)
Data unavailable 2 (5%)
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Fig. 2d). Six patients were taking antihypertensive med-
ication. No differences in either autonomic dysfunction
or fatigue severity scores was seen between those taking
and those not taking antihypertensive medication.
Depression was not a frequent cause of fatigue in PSC
with only two patients (one fatigued and one non-fati-
gued) reaching caseness. No association was seen
between serum biochemistry parameters and fatigue
severity in either the PSC or the PBC group. In the PSC
group, fatigue severity was unrelated to whether disease
was intra- or extrahepatic in type (FIS 21.1 ± 9.9, 27%
fatigued; 28.7 ± 6.8, 37% fatigued respectively, both
P = ns).
The association between autonomic dysfunction
symptoms and fatigue was not seen in all COMPASS
domains, being restricted to Orthostatic Intolerance and
Secretomotor (Fig. 3a, b). No association was seen with
other domains such as Autonomic GI (Fig. 3c). Given its
apparent importance in fatigue pathogenesis in PSC, we
went on to explore the organic basis of the orthostatic
intolerance symptoms using dynamic testing.
Dynamic testing of haemodynamic responses to standing
in non-transplanted PSC patients
Ten representative non-transplanted PSC patients
(mean FIS 24.6 ± 29.0) and matched normal controls
underwent formal autonomic assessment. Neurally
mediated hypotension was found in six PSC patients
(60%) compared to 1 (8%) in the control group
(a) (b)
Fig. 1. (a) Comparison of fatigue severity (assessed using FIS) between patients with PSC (n = 40), community (n = 40) and PBC control
populations (n = 40). Broken line represents the mean + 2SD for fatigue severity in the control population, this study definition for significant
fatigue. (b) Frequency of significant fatigue defined using this study cut-off in PSC patients and community and PBC controls.
(b)
(d)
(a)
(c)
Fig. 2. (a) Severity of daytime somnolence (assessed using the ESS) in PSC patients (n = 40) and community (n = 40) and PBC controls
(n = 40). (b) Severity of autonomic symptoms (assessed using COMPASS) in PSC patients and community and PBC controls and (c) their rela-
tionship with fatigue severity in PSC patients. (d) Fatigue severity scores in PSC patients with and without autonomic dysfunction (AD) symp-
toms.
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(P = 0.05). Assessment of autonomic parameters at
baseline (over 10 min resting supine) confirmed that,
compared to controls population, the PSC group had
increased sympathetic activity [increased low frequency
(LF) heart rate variability] and reduced parasympathetic
activity [reduced high frequency (HF) heart rate vari-
ability; Fig. 4a, b]. Heart rate at rest, in response to
standing for 40 min and during recovery correlated sig-
nificantly with increasing fatigue in the PSC group
(Fig. 4c–e). Taken together, the dynamic autonomic
testing confirmed the presence of overt autonomic vaso-
motor control abnormality, linked to fatigue severity,
and suggested a shift in the balance of autonomic reac-
tivity from parasympathetic (down-regulated) to sym-
pathetic (up-regulated).
Symptom impact in PSC patient subgroups
Primary sclerosing cholangitis is not a condition which
exists in isolation. The association with IBD, a condition
itself associated with both fatigue and autonomic dys-
function, presents a potential confounding process. Sig-
nificant fatigue was seen in both patients without and
with intercurrent IBD (Fig. S1a,b). Fatigue was more
severe and more frequently seen in patients with IBD
compared with patients without, although these differ-
ences did not reach statistical significance. The level of
fatigue seen in PSC patients with IBD mirrored that seen
in the control group of patients with IBD in the absence
of PSC, (n = 20) who were group-matched in terms of
age (53.4 ± 16.7 vs 52.5 ± 14.2) and gender (75% male
in each group) to the PSC patients with IBD, and all of
whom had quiescent or only mildly active colitis. Both
PSC and IBD and PSC alone patients exhibited signifi-
cant autonomic symptoms (Fig. S1c). In both groups,
the severity of fatigue correlated with the level of
autonomic symptoms (Fig. S1d). Within the group of
patients with both PSC and IBD, the severity of both
fatigue and autonomic symptoms was significantly
increased in the subgroup of patients who had under-
gone significant surgical intervention (colectomy and il-
eostomy/pouch formation) (Fig. S2a,b). Within the PSC
group, no difference in fatigue severity was seen between
patients who were and were not receiving UDCA ther-
apy (Fig. S2c). This study was not designed or powered
to address the question of fatigue in post-transplant
PSC patients but it was striking that fatigue was a signif-
icant ongoing problem in post-transplant patients, with
severity levels that were higher than those seen in the
non-transplanted PSC patients, although this difference
did not reach statistical significance (Fig. S2d).
Discussion
In this study, we set out to explore the prevalence,
degree and associations of fatigue in a comprehensive
and representative single-centre cohort of PSC patients
and, in particular, to explore potential factors contribut-
ing to fatigue in patients experiencing it. The patients in
this study were not selected for clinical phenotype and
were not subject to referral bias, all coming from the
local centre catchment area. The assessment tools used
are well-described and validated measures optimized for
patient self-completion. This study was controlled with
age- and sex-matched community controls from the
same geographical area, as well as patients with IBD in
(a) (b)
(c)
Fig. 3. Fatigue severity in PSC (n = 40) correlates directly with the (a) Orthostatic Intolerance and (b) Secretomotor domains of the COM-
PASS but not other domains including the (c) Autonomic GI.
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whom PSC had been actively excluded and patients with
PBC. Within this cohort, fatigue levels were significantly
higher than in the community controls, and similar to
those in the PBC patients, with 35% of PSC patients
experiencing significant fatigue (defined using a cut-off
of mean + 2SD for the community controls). Fatigue is
a problem in PSC and one which impacts on a signifi-
cant minority of patients. It is unrelated in severity to
conventional markers of disease severity and disease dis-
tribution. The key association of fatigue in PSC appears
to be with autonomic dysfunction suggesting a potential
target for therapeutic intervention.
Unlike PBC, where fatigue is strongly associated with
both autonomic dysfunction and daytime somnolence
(12, 15, 16, 25, 26,) fatigue in the study cohort was only
associated with autonomic dysfunction. Among the sig-
nificant minority of PSC patients with significant auto-
nomic symptoms, fatigue is very marked and almost
universal (approximately 80%). In contrast, among
patients without autonomic dysfunction, mean fatigue
scores were no different to those seen in community
controls. Overt depression was also an uncommon cause
of fatigue in our cohort in contrast to previous findings
(7). In our cohort, fatigue was slightly more severe in
patients with both PSC and IBD (reaching levels similar
to those seen in IBD only controls), but was, crucially,
still significant in patients with PSC alone. The specific
association with autonomic dysfunction was seen in
both PSC and IBD and PSC alone patient groups.
Although this study was not designed to explore the
impact of UDCA use on fatigue (the specific reasons for
UDCA use in individual patients, which may have
included worse symptoms, were not recorded for exam-
ple) there was no evidence that UDCA use was associ-
ated with lower fatigue levels. This mirrors the situation
in PBC, where there is no evidence to suggest that
UDCA reduces fatigue severity (27). Within the PSC
and IBD patient group, the nature of the IBD and, in
particular the need for previous surgery impacted signif-
icantly on fatigue. Patients with quiescent colitis who
had not undergone surgical intervention had signifi-
cantly lower levels of fatigue than post-colectomy
patients. Again, the higher levels of fatigue in the post-
surgical patients were strongly related to increased levels
of autonomic dysfunction symptoms in this group. The
findings of this element from this study would suggest
that the fatigue experienced by PSC patients has compo-
nents related to PSC itself, as well as aspects relating to
the presence of co-existent IBD in some patients. It is
likely that approaches to effective therapy will be equally
complex and must take account of the different predis-
posing disease processes.
Although autonomic dysfunction symptoms were
strongly associated with fatigue where present, in PSC,
the effect was not uniform across the spectrum of such
symptoms. In fact, the fatigue association was specific
(a) (b)
(c) (d) (e)HR at rest HR in response to standing HR during recovery
Fig. 4. Objective assessment of autonomic dysfunction in a representative subgroup of PSC patients (n = 10). Compared to age- and sex-
matched community controls (n = 10) PSC patients have (a) significantly increased low frequency heart rate variability and (b) significantly
decreased high frequency heart rate variability. Correlation between heart rate and fatigue severity in PSC patients (c) at rest (d) after
40 min tilt and (e) during recovery.
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for the orthostatic intolerance and secretomotor
domains of the COMPASS. The orthostatic intolerance
association, which again mirrors that seen in PBC, other
fatigue-associated liver diseases such as NAFLD and
non-liver conditions such as chronic fatigue syndrome,
suggests the potential presence of abnormal posture-
associated blood pressure regulation which, in the case
of PBC, reflects acquired baroreceptor reflex insensitiv-
ity (23). A specific association with orthostatic intoler-
ance would potentially explain the worsening of fatigue
in PSC patients with IBD treated by colectomy where
fluid homeostasis issues, which could exacerbate the
expression of baroreceptor reflex insensitivity, are fre-
quent.
Given the apparent strength of the link between
orthostatic intolerance, autonomic symptoms and fati-
gue in PSC, we set out to undertake, for the first time in
this disease, formal assessment of autonomic haemody-
namic regulation using established approaches adopted
in other disease settings including PBC. These studies
confirmed the presence of significant heart rate variabil-
ity abnormality in PSC (a feature of autonomic dysfunc-
tion) with features suggestive of increased sympathetic
and decreased parasympathetic tone. Tilt-testing,
undertaken here in PSC for the first time, showed a sig-
nificant correlation between heart rate at all phases of
the tilt and fatigue severity, with tachycardia (again
reflecting the parasympathetic to sympathetic tone shift)
strongly associating with fatigue. These findings would
all be in keeping with variable baroreceptor reflex insen-
sitivity in PSC, with over-utilization of sympathetic
escape pathways, with levels of insensitivity and escape
directly linked to fatigue. This model would explain the
association between fatigue in PSC and both orthostatic
intolerance symptoms (a direct manifestation of the
baroreceptor reflex insensitivity) and secretomotor
symptoms (a manifestation of sympathetic escape).
This study has limitations. The first is that the associ-
ation between autonomic dysfunction and fatigue in
PSC is currently correlative rather than mechanistic in
nature. However, the apparent association between
worse fatigue and increased autonomic dysfunction in
patients with surgically treated IBD (colectomy and
ileostomy or pouch procedure), where fluid-balance
challenges are well recognized, hints at a mechanism.
Any causal role for autonomic dysfunction in fatigue in
PSC will only be confirmed by undertaking trials of the
efficacy of treatments able to reverse vasomotor auto-
nomic dysfunction in terms of reducing fatigue severity.
We believe that such trials are warranted. A further limi-
tation was that the assessment of fatigue was only
undertaken through subjective assessment approaches
with no objective assessment of physical activity
attempted. However, studies in PBC have demonstrated
that perceived fatigue is associated with reduced physi-
cal activity levels. This raises the possibility that decon-
ditioning may contribute to the clinical expression of
fatigue and autonomic dysfunction in PSC, potentially
exacerbating the phenotype. Again, intervention studies
will be needed to dissect out these complex relation-
ships. A further limitation is study size, a potential fac-
tor in explaining the differences in fatigue severity
between this and other studies in the field. Very large
scale cohort studies akin to those being performed in
PBC on national scale cohorts would be very helpful in
definitively addressing this important issue.
Our finding of significant levels of fatigue in PSC is
seemingly at odds with the other large series in this dis-
ease (7, 10). There are several potential explanations for
the apparent discrepancy including study size, case mix
differences and psycho-social functioning differences
between populations [the same group reported no
excess fatigue in PBC in their Scandinavian population;
a finding at odds with most other studies in Northern
European populations (28)] and the nature of control
groups. In practice, however, the studies have a similar
finding of significant fatigue as a feature in a minority of
PSC patients, with lower levels experienced at lower fre-
quency than is the case in PBC (6, 28) and, as might be
expected, cases of significant fatigue being seen in the
community controls population. This study adds signif-
icantly to our understanding by identifying the sub-
group of patients with PSC, who experience significant
fatigue as those patients experiencing significant auto-
nomic dysfunction. The strength of the association
reported here between autonomic dysfunction and fati-
gue in PSC will help the clinical management of PSC
patients through identifying patients at risk (autonomic
dysfunction screening tools are very acceptable to
patients and can be used in the ordinary clinic setting)
and suggesting possible approaches to therapy through
application of well-described orthostatic intolerance
treatment paradigms.
The findings of this study, and in particular the simi-
larities and differences between fatigue associations in
PSC and those previously reported in PBC, add to our
understanding of the complex systemic symptoms of
chronic cholestatic disease. Autonomic dysfunction is
frequent in PBC and is strongly associated with both
fatigue and low level cognitive impairment (29). It is
associated with both organic brain lesions on magnetic
resonance imaging and impairment of cerebral autore-
gulation (29, 30). These findings are compatible with
structural change in brain areas regulating autonomic
function as a consequence either of cholestasis or the
underpinning disease process in PBC. This organic
brain injury model would potentially explain the ongo-
ing presence of fatigue in PBC following liver transplan-
tation (31), and the direct link between the severity of
that fatigue and degree of ongoing autonomic dysfunc-
tion. The findings of this study, showing similar effects
in a second cholestatic liver disease, would support cho-
lestasis rather than a disease-specific aetiological factor
in central autonomic dysfunction in PBC. The apparent
continuation of PSC fatigue following liver transplanta-
tion (within the limitations of this study design), and
Liver International (2015)
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the ongoing association with autonomic symptoms in
the post-transplant patients would further support the
cholestatic injury model for autonomic dysfunction.
Fatigue levels seen in this study in PSC are somewhat
lower than those in the PBC control groups (which
themselves mirrored previous findings in PBC made in
studies using similar methodologies). An explanation
for this could be the absence in PSC patients of the addi-
tional processes thought to contribute to fatigue expres-
sion. These include daytime somnolence which was not
a significant factor in PSC patients, and an apparent
direct metabolic effect of antimitochondrial antibodies
which are absent in PSC patients (32). In our model for
metabolic fatigue in PBC, an underlying metabolic
abnormality linked to the specific immune response in
the condition is compensated for by vascular and trans-
porter processes which are subject to autonomic regula-
tion. Severe fatigue, according to this model, results
from a dual process of primary metabolic fatigue exacer-
bated by a failure to compensate as a consequence of
autonomic dysfunction occurring as a second disease
process. In this model, autonomic dysfunction occur-
ring in any disease setting could, if severe enough,
impair the recovery from normal muscle metabolic
activity in the context of exercise (as opposed to the
enhanced metabolic state seen in PBC). We propose this
as a generic model for autonomic dysfunction-associ-
ated fatigue. If this model is correct, the conclusion of
this study would be that PSC patients do indeed experi-
ence the same type of fatigue as is seen sporadically in
the normal population, but they do so more frequently
and to a greater degree because of their predisposition
to cholestasis-induced autonomic dysfunction exacer-
bated in some patients by the fluid-balance effects of
their IBD surgery.
In conclusion, fatigue is a significant problem in a
minority of PSC patients. Symptom association data,
together with the pilot objective autonomic function
assessments, suggest it is associated with autonomic dys-
function. Clinical association data suggest it is exacer-
bated by other interventions and disease states, which
make autonomic dysfunction or its features worse. Fur-
ther confirmatory studies in larger cohorts are required.
If the associations outlined here are confirmed, screening
for and then treating autonomic dysfunction could rep-
resent an interesting potential approach to treating PSC
fatigue which would itself warrant future exploration.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Fig. S1. (a) Fatigue severity and (b) Significant fatigue
frequency in the subgroups of PSC patients without
(n = 16) and with associated IBD (n = 24) in compari-
son with community (n = 40) and IBD alone controls
(n = 20). (c) Autonomic dysfunction symptoms in the
subgroups of PSC patients with and without IBD and
(d) the association between fatigue severity and auto-
nomic symptom severity in the two groups. Open circles
and broken line PSC only, solid circles and solid line
PSC + IBD.
Fig. S2. (a) Fatigue severity and (b) Autonomic
symptom severity in PSC and IBD patients with (n = 8)
and without (n = 16) significant surgery (colectomy &
ileostomy/pouch formation). (c) Fatigue severity in PSC
patients treated (n = 25) and not-treated (n = 15) with
UDCA. (d) Fatigue severity in PSC patients compared
to the Newcastle cohort of transplanted PSC patients
(n = 11).
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